Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

References

• DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. New Engl J Med 1995;333:541–9
   Google Scholar
• Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose response trial. Am J Med 1997;102:491–7
   Google Scholar
• Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin–sulfonylurea treatment of patients with noninsulin dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992;74:1020–6
   PubMed Web of Science ®Google Scholar
• Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res Suppl 1985;15:105–11
   PubMedGoogle Scholar
• Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993;42:1217–22
   PubMed Web of Science ®Google Scholar
• Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987;10:62–7
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294–301
   Google Scholar
• Perriello G, Misericordia P, Volpi E, et al. Acute anti-hyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994;43:920–8
   Google Scholar
• Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pederson O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 1989;120:257–65
   Google Scholar
• Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696–704
   PubMed Web of Science ®Google Scholar
• Widen EI, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992;41:354–8
   Google Scholar
• Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl J Med 1995;333:550–4
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346: 393–403
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–65
   Google Scholar
• Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy. Diabetes Obes Metab 2002;4: 368–75
   Google Scholar
• Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. Ann Intern Med 1999;131: 182–8
   Google Scholar
• Glucophage® [metformin hydrochloride tablets] and Glucophage® XR [metformin hydrochloride extended-release tablets] Product Information, Bristol-Myers Squibb Company, Princeton, NJ 08543 USA, Revised July 2002
   Google Scholar
• Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6:472–4
   PubMed Web of Science ®Google Scholar
• Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther 2003;25: 515–29
   Google Scholar
• Hebden JM, Gilchrist PJ, Blackshaw E, et al. Night-time quiescence and morning activation in the human colon: effect on transit of dispersed and large single unit formulations. Eur J Gastroenterol Hepatol 1999;11:1379–85
   PubMed Web of Science ®Google Scholar
• Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991;17:224–31
   PubMed Web of Science ®Google Scholar
• Howlett HC, Bailey CJ. A risk–benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489–503
   PubMed Web of Science ®Google Scholar